ArticleClinical genitourinary cancer2021

A Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Versus Pembrolizumab Plus Axitinib and Versus Avelumab Plus Axitinib in First-Line Treatment of Advanced Renal Cell Carcinoma.

Rebecca Shay et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.